Welcome to NGC. Skip directly to: Search Box, Navigation, Content.


Brief Summary

GUIDELINE TITLE

Pain management. In: Evidence-based geriatric nursing protocols for best practice.

BIBLIOGRAPHIC SOURCE(S)

  • Horgas AL, Yoon SL. Pain management. In: Capezuti E, Zwicker D, Mezey M, Fulmer T, editor(s). Evidence-based geriatric nursing protocols for best practice. 3rd ed. New York (NY): Springer Publishing Company; 2008. p. 199-222. [70 references]

GUIDELINE STATUS

This is the current release of the guideline.

This guideline updates a previous version: Horgas AL, McLennon SM. Pain management. In: Mezey M, Fulmer T, Abraham I, Zwicker DA, editor(s). Geriatric nursing protocols for best practice. 2nd ed. New York (NY): Springer Publishing Company, Inc.; 2003. p. 229-50.

BRIEF SUMMARY CONTENT

 
RECOMMENDATIONS
 EVIDENCE SUPPORTING THE RECOMMENDATIONS
 IDENTIFYING INFORMATION AND AVAILABILITY
 DISCLAIMER

 Go to the Complete Summary

RECOMMENDATIONS

MAJOR RECOMMENDATIONS

Note from the National Guideline Clearinghouse (NGC): In this update of the guideline, the process previously used to develop the geriatric nursing protocols has been enhanced.

Levels of evidence (I – VI) are defined at the end of the "Major Recommendations" field.

Assessment Parameters

  • Assumptions
    • The majority of hospitalized older patients suffer from both acute and persistent pain.
    • Older adults with cognitive impairment experience pain but are often unable to verbalize it (Smith, 2005 [Level I]).
    • Both patients and health care providers have personal beliefs, prior experiences, insufficient knowledge, and mistaken beliefs about pain and pain management that:
      • Influence the pain management process
      • Must be acknowledged before optimal pain relief can be achieved (American Geriatric Society [AGS], 2002 [Level VI]).
    • Pain assessment must be regular, systematic, and documented in order to accurately evaluate treatment effectiveness (AGS, 2002 [Level VI]).
    • Self-report is the gold standard for pain assessment (AGS, 2002 [Level VI]).
  • Strategies for pain assessment
    • Review medical history, physical examinations, and laboratory and diagnostic tests to understand the sequence of events contributing to pain (AGS, 2002 [Level VI]).
    • Assess present pain, including intensity, character, frequency, pattern, location, duration, and precipitating and relieving factors (AGS, 2002 [Level VI]).
    • Review medications, including current and previously used prescription drugs, over-the-counter drugs, and home remedies. Determine which pain control methods have previously been effective for the patient. Assess patient's attitudes and beliefs about use of analgesics, adjuvant drugs, and nonpharmacological treatments (AGS, 2002 [Level VI]).
    • Use a standardized tool to assess self-reported pain. Choose from published measurement tools, and recall that older adults may have difficulty using 10-point visual analog scales. Vertical verbal descriptor scales or faces scales may be more useful with older adults (Taylor et al., 2005 [Level V]).
    • Assess pain regularly and frequently, but at least every 4 hours. Monitor pain intensity after giving medications to evaluate effectiveness.
    • Observe for nonverbal and behavioral signs of pain, such as facial grimacing, withdrawal, guarding, rubbing, limping, shifting of position, aggression, agitation, depression, vocalization, and crying. Also watch for changes in behavior from patient's usual patterns (Taylor et al., 2005 [Level V]).
    • Gather information from family members about the patient's pain experiences. Ask about patient's verbal and nonverbal/behavioral expressions of pain, particularly in older adults with dementia.
    • When pain is suspected but assessment instruments or observation is ambiguous, institute a clinical trial of pain treatment (i.e., in persons with dementia). If symptoms persist, assume pain is unrelieved and treat accordingly (Herr, et al., 2006 [Level VI]).

Nursing Care Strategies

  • Prevention of pain
    • Assess pain regularly and frequently to facilitate appropriate treatment (AGS, 2002 [Level VI]).
    • Anticipate and aggressively treat for pain before, during, and after painful diagnostic and/or therapeutic treatments (AGS, 2002 [Level VI]).
    • Educate patients, families, and other clinicians to use analgesic medications prophylactically prior to and after painful procedures (AGS, 2002 [Level VI]).
    • Educate patients and families about pain medications, their side effects and adverse effects, and issues of addiction, dependence, and tolerance (AGS, 2002 [Level VI]).
    • Educate patients to take medications for pain on a regular basis and to avoid allowing pain to escalate (AGS, 2002 [Level VI]).
    • Educate patients, families, and other clinicians to use nonpharmacological strategies to manage pain, such as relaxation, massage, and heat/cold (AGS, 2002 [Level VI]).
  • Treatment guidelines
    • Pharmacologic (AGS, 2002 [Level VI])
      • Older adults are at increased risk for adverse drug reactions.
      • Monitor medications closely to avoid over- or under-medication.
      • Administer pain drugs on a regular basis to maintain therapeutic levels; avoid as occasion requires (prn) drugs.
      • Document treatment plan to maintain consistency across shifts and with other care providers.
      • Use equianalgesic dosing and World Health Organization (WHO) three-step ladder to obtain optimal pain relief with fewer side effects (WHO, 1996).
    • Nonpharmacologic (AGS, 2002 [Level VI])
      • Investigate older patients' attitudes and beliefs about, preference for, and experience with nonpharmacological pain treatment strategies.
      • Tailor nonpharmacologic techniques to the individual.
      • Cognitive-behavioral strategies focus on changing the person's perception of pain (e.g., relaxation therapy, education, and distraction), and may not be appropriate for cognitively impaired persons.
      • Physical pain relief strategies focus on promoting comfort and altering physiologic responses to pain (e.g., heat, cold, transcutaneous electrical nerve stimulation [TENS] units) and are generally safe and effective.
    • Combination approaches that include both pharmacological and nonpharmacological pain treatments are often the most effective.
  • Follow-up assessment
    • Monitor treatment effects within 1 hour of administration and at least every 4 hours.
    • Evaluate patient for pain relief and side effects of treatment.
    • Document patient's response to treatment effects.
    • Document treatment regimen in patient care plan to facilitate consistent implementation.

Definitions:

Level I: Systematic reviews (integrative/meta-analyses/clinical practice guidelines based on systematic reviews)

Level II: Single experimental study (randomized controlled trials [RCTs])

Level III: Quasi-experimental studies

Level IV: Non-experimental studies

Level V: Care report/program evaluation/narrative literature reviews

Level VI: Opinions of respected authorities/Consensus panels

Reprinted with permission from Springer Publishing Company: Capezuti, E., Zwicker, D., Mezey, M. & Fulmer, T. (Eds). (2008) Evidence Based Geriatric Nursing Protocols for Best Practice, (3rd ed). New York: Springer Publishing Company.

CLINICAL ALGORITHM(S)

None provided

EVIDENCE SUPPORTING THE RECOMMENDATIONS

REFERENCES SUPPORTING THE RECOMMENDATIONS

TYPE OF EVIDENCE SUPPORTING THE RECOMMENDATIONS

The type of supporting evidence is identified and graded for selected recommendations.

IDENTIFYING INFORMATION AND AVAILABILITY

BIBLIOGRAPHIC SOURCE(S)

  • Horgas AL, Yoon SL. Pain management. In: Capezuti E, Zwicker D, Mezey M, Fulmer T, editor(s). Evidence-based geriatric nursing protocols for best practice. 3rd ed. New York (NY): Springer Publishing Company; 2008. p. 199-222. [70 references]

ADAPTATION

Adapted from:

  • American Geriatrics Society Panel on Chronic Pain in Older Adults. (1998). The management of chronic pain in older persons. Journal of the American Geriatrics Society, 46, 635-651.
  • Glen, V. L. & St. Marie, B. (2002). Overview of pharmacology. In B. St. Marie (Ed.), American Society of Pain Management Nurses: Core curriculum for pain management nursing. Philadelphia: W. B. Saunders Company.
  • McCaffery, M. & Portenoy, R. (1999). Nonopiods. In M. McCaffery & C. Pasero (Eds.), Pain clinical manual (2nd ed.). St. Louis: Mosby.

DATE RELEASED

2003 (revised 2008 Jan)

GUIDELINE DEVELOPER(S)

Hartford Institute for Geriatric Nursing - Academic Institution

GUIDELINE DEVELOPER COMMENT

The guidelines were developed by a group of nursing experts from across the country as part of the Nurses Improving Care for Health System Elders (NICHE) project, under sponsorship of The John A. Hartford Foundation Institute for Geriatric Nursing.

SOURCE(S) OF FUNDING

Supported by a grant from The John A. Hartford Foundation.

GUIDELINE COMMITTEE

Not stated

COMPOSITION OF GROUP THAT AUTHORED THE GUIDELINE

Primary Authors: Ann L. Horgas and Saunjoo L. Yoon

FINANCIAL DISCLOSURES/CONFLICTS OF INTEREST

Not stated

GUIDELINE STATUS

This is the current release of the guideline.

This guideline updates a previous version: Horgas AL, McLennon SM. Pain management. In: Mezey M, Fulmer T, Abraham I, Zwicker DA, editor(s). Geriatric nursing protocols for best practice. 2nd ed. New York (NY): Springer Publishing Company, Inc.; 2003. p. 229-50.

GUIDELINE AVAILABILITY

Electronic copies: Available from the Hartford Institute for Geriatric Nursing Web site.

Copies of the book Geriatric Nursing Protocols for Best Practice, 3rd edition: Available from Springer Publishing Company, 536 Broadway, New York, NY 10012; Phone: (212) 431-4370; Fax: (212) 941-7842; Web: www.springerpub.com.

AVAILABILITY OF COMPANION DOCUMENTS

PATIENT RESOURCES

None available

NGC STATUS

This summary was completed by ECRI on February 2, 2004. The information was verified by the guideline developer on March 12, 2004. This summary was updated by ECRI on October 4, 2004 following the withdrawal of the drug Vioxx (Rofecoxib) and again on January 12, 2005 following the release of a public health advisory from the U.S. Food and Drug Administration regarding the use of some non-steroidal anti-inflammatory drug products. This summary was updated on April 15, 2005 following the withdrawal of Bextra (valdecoxib) from the market and the release of heightened warnings for Celebrex (celecoxib) and other nonselective nonsteroidal anti-inflammatory drugs (NSAIDs). This summary was updated by ECRI on June 16, 2005, following the U.S. Food and Drug Administration advisory on COX-2 selective and non-selective non-steroidal anti-inflammatory drugs (NSAIDs). This summary was updated by ECRI on June 23, 2008. The updated information was verified by the guideline developer on August 4, 2008.

COPYRIGHT STATEMENT

This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions.

DISCLAIMER

NGC DISCLAIMER

The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.

All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.

Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at http://www.guideline.gov/about/inclusion.aspx .

NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.

Readers with questions regarding guideline content are directed to contact the guideline developer.


 

 

   
DHHS Logo